The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to inhibit the enzyme has been explored. Several DPP-4 inhibitors are in clinical development; these are ...

GLP-1s reduced depression risk vs. DPP-4 inhibitors but not SGLT2 inhibitors. However, both GLP-1s and SGLT2 inhibitors may offer similar antidepressant benefits, researchers noted. The use of GLP ...

However, among 14,665 matched pairs of GLP-1 agonist and SGLT2 inhibitor users ... interpreted with caution," the researchers said. For example, patients who consistently adhered to their ...

The first two groups included 36,082 patients using GLP-1 receptor agonists and 234,028 patients using DPP-4 inhibitors between 2007 and 2020, while the other two groups included 32,336 patients ...

SGLT2 inhibitors and GLP-1RAs yielded lower risks for COPD exacerbation than DPP-4 inhibitors among patients with type 2 diabetes.

Opens in a new tab or window New GLP-1 receptor agonist users did not have an excess risk for suicidality compared with DPP-4 inhibitor and SGLT2 inhibitor users. They also didn't have an excess ...

However, for crude incidence rates there was an increased incidence of suicidality with GLP-1 receptor agonist vs DPP-4 inhibitor use; 3.9 vs 1.8 per 1000 person-years. HealthDay News — Glucagon ...

and colleagues compared the risk for depression in older adults with T2D initiating treatment with GLP-1 RAs vs sodium-glucose cotransporter-2 inhibitors (SGLT-2is) or DPP-4is in a target trial ...

However, compared to participants taking dipeptidyl peptidase-4 inhibitors (DPP4is), GLP ... be generalized to all people who use GLP-1RAs. For example, the results cannot necessarily be ...

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.